Last reviewed · How we verify
Darunavir, Ritonavir, Truvada
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 prevention (pre-exposure prophylaxis with Truvada component).
At a glance
| Generic name | Darunavir, Ritonavir, Truvada |
|---|---|
| Also known as | Prezista, Norvir, Truvada |
| Sponsor | Imperial College London |
| Drug class | Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase, CYP3A4 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Darunavir is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing darunavir levels. Truvada (tenofovir/emtricitabine) are nucleoside reverse transcriptase inhibitors that block viral reverse transcriptase. Together, they suppress HIV replication through multiple mechanisms.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 prevention (pre-exposure prophylaxis with Truvada component)
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated lipids
- Renal impairment (Truvada component)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (PHASE3)
- Dual Therapy With Boosted Darunavir + Dolutegravir (PHASE3)
- Research In Viral Eradication of HIV Reservoirs (PHASE2)
- Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darunavir, Ritonavir, Truvada CI brief — competitive landscape report
- Darunavir, Ritonavir, Truvada updates RSS · CI watch RSS
- Imperial College London portfolio CI